NCT02098460已完成4 期
To Compare the Effect of Concomitant Administration of Probucol and Cilostazol with Probucol Single Treatment on the Atherosclerosis Related Markers (including the Thickness of the Achilles Tendon) and Evaluate Safety (based on Atorvastatin Treatment) in Severe Hypercholesterolemia Subject
适应症
干预措施
相关药物
试验速览
- 阶段
- 4 期
- 状态
- 已完成
- 入组人数
- 300
- 试验地点
- 1
- 主要终点
- the effect of concomitant administration of Probucol and Cilostazol on the mean achilles tendon thickness (ATT)
研究概览
简要总结
To evaluate the effect of concomitant administration of Probucol and Cilostazol (based on Atorvastatin treatment) on the atherosclerosis related markers (including the thickness of the Achilles tendon) in severe hypercholesterolemia subject, through the observation of the thickness of the Achilles tendon, the thickness of mean carotid intima-media, anti-oxidation biomarkers and serum lipid profile.
详细描述
Multicenter, randomized, controlled, single-blinded, three parallel arms study. Group A: Atorvastatin + Probucol-placebo + Cilostazol-placebo Group B: Atorvastatin + Probucol + Cilostazol-placebo Group C: Atorvastatin + Probucol + Cilostazol
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Triple (Participant, Care Provider, Investigator)
入排标准
- 年龄范围
- 18 Years 至 70 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •The subject whose voluntary written informed consent is obtained for participation in this study;
- •The subject with low-density lipoprotein cholesterol (LDL-C) ≥ 4.66 mmol/L (180 mg/dL) (the highest level either pre-treatment or on treatment);
- •The subject with ATT≥9mm.
排除标准
- •The subject with homozygous familial hyperlipidemia;
- •The subject who took Probucol within 6 months before the screening test;
- •The subject who took Cilostazol within 1 month before the screening test;
- •The subject who took Ezetimibe within 1 month before the screening test;
- •The subject who hoped to treat with Ezetimibe within this study period;
- •The subject being treated with Cyclosporine;
- •The subject with a history of hypersensitivity to Probucol and Cilostazol;
- •The subject with a triglyceride (TG) level greater than 4.52 mmol/L (400 mg/dL);
- •The subject with diabetes: HbA1c level greater than 8.4% (NGSP);
- •The subject with New York Heart Association (NYHA) classification: Class III and IV;
- •The subject with a QTc interval greater than 450 msec (male) or 470 msec (female);
- •The subject with serious ventricular arrythmias (frequent episodes of multifocal ventricular extrasystole);
- •The subject with atrial fibrillation (including paroxysmal atrial fibrillation);
- •The subject with congestive cardiac failure or unstable angina;
- •The subject with liver and renal functions that satisfy the following criteria within 28 days prior to start of the investigational medicinal product (IMP) administration.
- •AST ≥100 IU/L, ALT≥100 IU/L
- •Serum creatinine ≥1.5 mg/dL (133 µmol/L)
- •The subject who are participating in another clinical trial;
- •Woman during pregnancy or potential pregnancy, and breastfeeding;
- •Women of childbearing potential who are not agree to use an appropriate method of contraception;
- •The subject who are not considered by the Investigators to be appropriate to participate in this study for any other reasons.
研究组 & 干预措施
Probucol,Cilostazol
Placebo Comparator
Atorvastatin + Probucol-placebo + Cilostazol-placebo
干预措施: Atorvastatin, Probucol, Cilostazol (Drug)
Cilostazol
Placebo Comparator
Atorvastatin + Probucol+ Cilostazol-placebo
干预措施: Atorvastatin, Probucol, Cilostazol (Drug)
Probucol, Cilostazol
Active Comparator
Atorvastatin + Probucol + Cilostazol
干预措施: Atorvastatin, Probucol, Cilostazol (Drug)
结局指标
主要结局
the effect of concomitant administration of Probucol and Cilostazol on the mean achilles tendon thickness (ATT)
时间窗: at Month 6, 12 and 24
次要结局
- the additional effect of concomitant administration of Probucol and Cilostazol on mean carotid intima-media thickness (IMT)(at Month 12 and 24)
- the preventive effect of concomitant administration of Probucol and Cilostazol on the incidence of cerebrovascular and cardiovascular events (including intervention)(2 years)
- the effect of concomitant administration of Probucol and Cilostazol on biomarkers(2 years)
- the safety of Probucol or concomitant administration of Probucol and Cilostazol as determined by physical examination, vital signs, adverse events (AEs), laboratory examinations and 12-lead electrocardiogram (ECGs)(2 years)
研究者
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Evaluation of Concomitant Administration of Cilostazol and Probucol on Biomarkers, Endothelial Function and SafetyPeripheral Artery DiseaseNCT01142284Korea Otsuka Pharmaceutical Co., Ltd.80
已完成
4 期
Synergistic Effect of Combination Therapy With Cilostazol and Probucol on Plaque Stabilization and Lesion Regression: Serial Intravascular Ultrasound and Virtual Histology Study(SECURE Study)TherapyNCT01031667Yonsei University118
Unknown
Unknown
Combined Therapeutic Effect of Probucol and Cilostazol on Endothelial Function in Patients with Silent Cerebral Lacunar Infarcts and HypercholesterolemiaInvestigating the effect of combined therapy with probucol and cilostazol on endothelial function in patients with cerebral infarction and hypercholesterolemia.JPRN-jRCT1091220138Takase Bonpei20
已完成
4 期
Study of Cilostazol and Probucol to Assess Their Effects on Atherosclerosis Related BiomarkerType 2 Diabetes MellitusArteriosclerosis ObliteransNCT00823849Otsuka Beijing Research Institute200
招募中
3 期
Combining Use of Clopidogrel With Atorvastatin or Rosuvastatin in Patients With Large-vessel Ischemic StrokeIschemic StrokeNCT06360120Kafrelsheikh University600